Format

Send to

Choose Destination
Exp Mol Med. 2017 Jun 16;49(6):e345. doi: 10.1038/emm.2017.75.

Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.

Author information

1
Department of Microbiology and Parasitology, Universidad de Navarra, Pamplona, Spain.
2
Department of Intensive Care and Intermediate Care, University Hospital Aachen, Aachen, Germany.
3
Department of Anaesthesia and Intensive Care, University of Rostock, Rostock, Germany.
4
Department of Pharmacology and Toxicology, Universidad de Navarra, Pamplona, Spain.
5
National Institute of Advanced Industrial Science and Technology AIST, Takamatsu, Japan.
6
Department of Pathology, University Hospital of Luebeck, Luebeck, Germany.
7
Department of Pathology, Leibniz Research Center, Borstel, Germany.
8
Airway Research Center North (ARCN), Member of the German Center for Lung Research (DZL), Großhansdorf, Germany.
9
Medical Clinic III, Pulmonology/Infectious Diseases, University Hospital Schleswig-Holstein, Luebeck, Germany.
10
Division of Biophysics, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Borstel, Germany.

Abstract

Sepsis, which is induced by severe bacterial infections, is a major cause of death worldwide, and therapies combating the disease are urgently needed. Because many drugs have failed in clinical trials despite their efficacy in mouse models, the development of reliable animal models of sepsis is in great demand. Several studies have suggested that rabbits reflect sepsis-related symptoms more accurately than mice. In this study, we evaluated a rabbit model of acute sepsis caused by the intravenous inoculation of Salmonella enterica. The model reproduces numerous symptoms characteristic of human sepsis including hyperlactatemia, hyperglycemia, leukopenia, hypothermia and the hyperproduction of several pro-inflammatory cytokines. Hence, it was chosen to investigate the proposed ability of Pep19-2.5-an anti-endotoxic peptide with high affinity to lipopolysaccharide and lipoprotein-to attenuate sepsis-associated pathologies in combination with an antibiotic (ceftriaxone). We demonstrate that a combination of Pep19-2.5 and ceftriaxone administered intravenously to the rabbits (1) kills bacteria and eliminates bacteremia 30 min post challenge; (2) inhibits Toll-like receptor 4 agonists in serum 90 min post challenge; (3) reduces serum levels of pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor α); and (4) reverts to hypothermia and gives rise to temperature values indistinguishable from basal levels 330 min post challenge. The two components of the combination displayed synergism in some of these activities, and Pep19-2.5 notably counteracted the endotoxin-inducing potential of ceftriaxone. Thus, the combination therapy of Pep19-2.5 and ceftriaxone holds promise as a candidate for human sepsis therapy.

PMID:
28620220
PMCID:
PMC5519016
DOI:
10.1038/emm.2017.75
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center